Joris van Dongen

227 tSVF enriched facial lipofilling with PRP Table 1. In- and exclusion criteria of subjects participating in this study. BMI = body mass index Platelet-rich plasma and tissue-stromal vascular fraction preparation Prior to the surgery, 62 ml of whole blood was drawn from each subject in this study. 8 ml of anticoagulant citrate dextrose solution A (ACD-A) was added to 52 ml of whole blood and prepared following the Arthrex Angel system™ instructions. This resulted in 6 ml of non-activated PRP with a platelet concentration of 4 times the baseline. The other 10 ml of whole blood was collected in anACD-A syringe and was analyzed for the number of platelets. 60 ml of the harvested 100 ml of adipose tissue was used to create three times 1 ml of tSVFusing the previously described Fractionation of AdiposeTissue (FAT) procedure. 19 In short, all harvested adipose tissue was decanted and centrifuged at 3,000 rpm for 2.5 min. with a 9.5 cm radius fixed angle rotor (Medilite, Thermo Fisher Scientific, Waltham, MA) at room temperature (RT). After centrifugation, three times 10 ml of adipose tissue was mechanical dissociated with the use of a fractionator (a luer- to-luer transfer with three holes 1.4 mm inside, Tulip, Medical Products, San Diego, CA) by pushing lipoaspirate 30 times forward and backward. Then, the dissociated adipose tissue was again centrifuged at 3,000 rpm for 2.5 min. with a 9.5 cm radius fixed angle rotor (Medilite) at RT. 1 ml of tSVF was mixed with 2.5 ml of PRP and injected transcutaneously against the inside of the skin with the use of a 23G needle